BMRN Profile — BioMarin Pharmaceutical Inc
BioMarin Pharmaceutical is a global biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products include: Vimizim (elosulfase alpha); Naglazyme (galsulfase); Kuvan (sapropterin dihydrochloride); Palynziq (pegvaliase-pqpz); Brineura (cerliponase alfa); Voxzogo (vosoritide); and Aldurazyme (laronidase). Co.'s clinical development programs include: Valoctocogene roxaparvovec, which is an adeno associated virus (AAV5) vector drug development candidate; BMN 307, which is an AAV5 mediated gene therapy; and BMN 225, which is a small-molecule therapy.
|
|
Free BMRN Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Buy (3.36 out of 4) 54th percentile
(ranked higher than approx. 54% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |